Evicenter
P&T meetings

4D-150

Neovascular age-related macular degeneration

Regulatory submission
Not announced
Launch
Not announced
Last updated
180 sources

Product information and disease descriptionProduct descriptionProduct informationDosing and administration

Dosage

3 evidence topics · 4 sources

Single administration at the Phase 3 dose

“4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1” (opens the source at this quote in a new tab)

Dose selection across the clinical program

“In the Phase I/II PRISM trial, patients with nAMD received a single IVT administration across three dose cohorts (6 × 10⁹, 1 × 10¹⁰, and 3 × 10¹⁰ vg/eye).” (opens the source at this quote in a new tab)

“In addition, a consistent dose response was observed between 3E10 vg/eye, the selected Phase 3 dose, and the lower dose of 1E10 vg/eye.” (opens the source at this quote in a new tab)

Supplemental anti-VEGF injections after dosing

“Patients in both arms will be eligible for supplemental aflibercept injections.” (opens the source at this quote in a new tab)

Redosing, dose modification, and dosing of the fellow eye

No evidence found.